Ann: Quarterly Report and Appendix 4C, page-4

• The Carrick Institute has prepared the resulting data for submission for publication.

• The board and management are also planning increased marketing and PR activities in line with the anticipated release of the Clinical Trial results. Some of these activities have commenced including digital marketing and search engine optimisation projects to improve the visibility of Mente Autism.
• The board and management expect the current quarter to be pivotal for Neurotech as it readies itself for the US clinical trial results. Once these results are announced the company will prioritise its FDA submission for Mente Autism.

• Upon the release of the Clinical Trial results and availability of the new devices, further marketing materials and initiatives will also be deployed.

• Neurotech management continues its program of outreach to existing and potential distribution partners. It has commenced discussions with several potential distribution partners in new geographies, while preparing for sessions in H2 CY2018 with existing distribution partners to present the Clinical Trial results and introduce the new iteration of the Mente Autism device.

• In accordance with the Company’s commitment to quality control, no sales of obsolete stock occurred during the last quarter, with sales expected to recommence once the updated device is available, which is expected to be available to the market early in H2 CY2018.

• During January, Promosalute conducted a targeted online marketing campaign in Italy to attract interest in the Mente Autism device. Promosalute will be extending its online marketing activities in the coming months to target a wider audience. Promosalute has also advised that it will increase the number of ‘Autism and Neurofeedback Centres’ in the coming months, with the three previously announced centres now active. The role of these centres is to assess the suitability of potential patients for the Mente Autism device, offer pre-sales and post-sales services to customers as well as provide medical consultations as demand for the Mente Autism devices increases. Promosalute are continuing to actively engage with several medical professionals to increase awareness of Mente Autism and to build a network of key opinion leaders in Italy.

• Neurotech has already established a relationship with select key opinion leaders in Italy, from which management expects several endorsements to be received in the short term. The first new research devices have also been completed and are to be shipped to key opinion leaders imminently.

Sounds very good to me. Informative and encouraging. Sounds like the results are very close to being published now. The board and management of very confident that the results are going to be nothing short of outstanding.. "The board and management expect the current quarter to be pivotal for Neurotech as it readies itself for the US clinical trial results"

Very exciting!

Cheers

Red bar